Clinical Trials
6 trialsNCT00569127 2026-05-29
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03972488 2026-01-21
NETTER-2
Advanced Accelerator Applications
Phase 3 Active not recruiting
NCT01578239 2022-04-04
NETTER-1
Advanced Accelerator Applications
Phase 3 Completed
NCT00182754 2017-04-11
Octreotide in Treating Patients With Cancer-Related Malignant Ascites
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00412061 2014-11-21
RADIANT-2
Novartis
Phase 3 Completed
NCT00690430 2013-07-30
Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease
Novartis
Phase 3 Completed